SafeBiologics
ALLIANCE *for* SAFE BIOLOGIC MEDICINES

GaBi
GENERICS AND BIOSIMILARS INITIATIVE
Building trust in cost-effective treatments

KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US

measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients

Wednesday, 29 June 2022 | 10:00 am – 11:50 am (EDT)
Online Event

Agenda

Academic clinician with specialty in gastroenterology, pharmacist, patient, policymaker and market access expert will share their experience with biosimilars, highlighting successes and challenges, their perspectives on prescribing and switching of biosimilars, measures to increase biosimilar adoption, including the role of healthcare providers.

10:00 – 10:05	**Welcome** **Professor Philip J Schneider**, MS, FASHP, FASPEN, FFIP, Ohio State University
10:05 – 10:15	**Status update of biosimilars approved and marketed in Europe and the US** **Michael S Reilly**, Esq, Alliance for Safe Biologic Medicines
10:15 – 10:25	**European prescribers' trust in prescribing and switching of biosimilars** **Michael S Reilly**, Esq, Alliance for Safe Biologic Medicines
10:25 – 10:35	**US physicians' perspective in biologicals/biosimilars prescribing and substitution** **Ralph McKibbin**, MD, FACP, FACG, AGAF, Pennsylvania Society of Gastroenterology/ Digestive Disease National Coalition
10:35 – 10:45	**Sustainable biosimilars market in Europe – policy considerations** **Professor Philip J Schneider**, MS, FASHP, FASPEN, FFIP, Ohio State University
10:45 – 11:05	**Measures leading to successful uptake and the current state of market access of biosimilars in the US** **Chad Pettit**, MBA, Amgen
11:05 – 11:15	**Patients' perspective on biosimilars use – Europe and the US** **Andrew Spiegel**, Esq, Global Colon Cancer Association
11:15 – 11:45 Moderator Panelists	**Panel discussion and Q&A** **Professor Philip J Schneider**, MS, FASHP, FASPEN, FFIP **Michael S Reilly**, Esq **Ralph McKibbin**, MD, FACP, FACG, AGAF **Chad Pettit**, MBA **Andrew Spiegel**, Esq

Register >

The discussion will continue at the next webinar on 'Non-medical switching of biologicals/biosimilars: Canada, Europe, the US' in July 2022. More information will be available soon.